The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant
- 366 Downloads
Neuroendocrine neoplasms (NENs) are increasing in incidence and prevalence. This reflects greater clinical awareness, effective imaging, and increasing pathological diagnostic recognition. Although the identification and treatment of clinical neuroendocrine syndromes are established, there is confusion when a NEN has no discernible clinical symptoms.
Nonfunctional tumors are usually diagnosed incidentally and at a later stage largely because either they do not secrete a bioactive product or do so, but in a form that is either inactive or in quantities that have no discernible effect. Nevertheless, the histopathology is indistinguishable from functional NENs, and tumors exhibit somatostatin receptor expression, and positive immunohistochemistry for neuroendocrine cell markers (CgA, NSE/synaptophysin). Similarly, their rates of growth and metastatic behavior are, like other NENs, predictably based on staging and grading (mitotic rate and Ki67 expression). Both types are diagnosed biochemically (CgA) and by imaging in an identical fashion with computed tomography, magnetic resonance imaging, somatostatin receptor scintigraphy, and endoscopic ultrasound. NENs, irrespective of function or bioactive secretory profile, respond with equal efficacy to the same regimen of surgery or antitumor drugs (e.g., somatostatin analogs with or without tyrosine kinase inhibitors/antiangiogenics or cytotoxics) depending on grade. Given the efficacy of somatostatin analogs in increasing progression free survival, nonfunctional NENs should be managed identically to symptomatic NENs. The consideration of NENs as functional or nonfunctional is an archaic clinical concept that should be discarded since the tumors are indistinguishable at a cellular, biological, and morphological level. All current evidences indicate that their diagnosis and treatment should follow the same common principles.
KeywordsCarcinoid Functional Epidemiology Incidence Nonfunctional Pancreatic neuroendocrine tumor SEER Survival
MK was supported in part by NIH: DK080871. BL was supported in part by a grant from the Genesis Oncology Trust, Auckland, New Zealand.
Conflicts of interest
- 17.Oberndorfer S. Karzinoide tumores des Dunndarms. Frankf Z Pathol. 1907:426–443Google Scholar
- 18.DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumours, pathology and genetics of tumours of endocrine organs. IARC, LyonGoogle Scholar
- 20.Bosman F, Carneiro F, Hruban R, Theise N (2010) WHO classification of tumours of the digestive system. WHO/IARC, LyonGoogle Scholar
- 37.Rinke A, Muller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663PubMedCrossRefGoogle Scholar
- 38.Ganti AK, West WW, Lackner RP, Kessinger A (2010) Current concepts in the diagnosis and management of small-cell lung cancer. Oncology (Williston Park) 24(11):1034–1039Google Scholar
- 42.Panzuto F, Severi C, Cannizzaro R et al (2004) Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Investig 27(1):6–11Google Scholar
- 50.Papotti M, Bongiovanni M, Volante M et al (2002) Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440(5):461–475PubMedCrossRefGoogle Scholar
- 68.Pavel M, Hainsworth JD, Baudin E, et al. (2010) A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide lar vs placebo + octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol 21(Suppl 8):Abst LBA8Google Scholar
- 69.Yao JC, Shah MH, Ito T, et al. (2010) A randomized, double-blind, placebo-controlled, multicenter phase iii trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). Ann Oncol 21(Suppl 8):Abst LBA9Google Scholar
- 70.Kulke M, Blaszkowsky L, Zhu A, Flortio S, Regan E (2010 ) Phase I/II study of everolimus (RAD001) in combination with Temozolamide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). Proc Am Soc Clin Oncol Gast Int:Abstr 223Google Scholar